SILVER SPRING, Md., Sept. 14 /PRNewswire/ -- The National Association of School Nurses (NASN) announced today the kickoff of S.C.R.A.T.C.H.

Sciele Pharma, Inc., a Shionogi Company, today announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S.

Sciele Pharma, Inc.: -- Statistically and clinically significant increase in all three co-primary endpoints -- Well tolerated and devoid of systemic side effects Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora"-AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced that the European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation ('PE') has met its three co-primary endpoints of Intravaginal Ejaculation Latency Time ('IELT') and Index of Premature Ejaculation ('IPE'; Ejaculatory Control and Sexual Satisfaction domains).

Sciele Pharma, Inc., a Shionogi Company, today announced that Addrenex Pharmaceuticals, Inc. has initiated its Phase II clinical trial with ADX415 for the treatment of hypertension. This is a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study that will involve 80 patients.

On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the completion of Shionogi's acquisition of Sciele for US$31.00 per share in cash.